2. >>Archive

One Cell Systems (US) to combine gel microdrop (GMD) with fluorescence activated cell sorting (FACS)

One Cell Systems (US) has received a $100,000 grant from the US NIH to evaluate the combined use of its gel microdrop technology and fluorescence activated cell sorting (FACS) to develop a rapid method for screening micro-organisms. The encapsulating technology, licensed to One Cell by the Harvard-Massachusetts Institute of Technology, is said to be well suited to automation as it is compatible with a broad spectrum of existing sample preparation and analytical technologies.

One Cell Systems (US) has received a $100,000 grant from the US NIH to evaluate the combined use of its gel microdrop technology and fluorescence activated cell sorting (FACS) to develop a rapid method for screening micro-organisms. The encapsulating technology, licensed to One Cell by the Harvard-Massachusetts Institute of Technology, is said to be well suited to automation as it is compatible with a broad spectrum of existing sample preparation and analytical technologies.

Founded in 1991, Cambridge, Massachusetts-based One Cell Systems has been financed by venture capital, research grants and development agreements with biopharmaceutical companies. Among projects funded by the NIH are assay development for HIV and TB testing

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 
• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight